LY2784544

LY2784544

CAT N°: 16705
Price:

From 92.00 78.20

LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)-imidazo[1,2-b]pyridazin-6-amine
  • Correlated keywords
    • 1229236-87-6 biochemical inhibitor kinase protein kinase cancer intracellular signaling signal transduction gandotinib LY 2784544 potent inhibit ATP-competitive janus kinase 2 JAK2 JAK JAK3 3 V617F mutation block STAT5 STAT 5 phosphorylation proliferation Ba/F3 pro-B-cells proB oral gavage reduce reduction growth SCID mice hematological malignancy malignancies
  • Product Overview:
    LY2784544 is a potent, ATP-competitive inhibitor of janus kinase 2 (JAK2) that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively).{27398} It also inhibits JAK2 containing the V617F mutation (IC50 = 20 nM), blocking STAT5 phosphorylation and proliferation of Ba/F3 pro-B-cells expressing this constitutively active JAK2 mutant form.{27398} When given by oral gavage, LY2784544 significantly reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets.{27398} JAK inhibitors, including LY2784544, may be useful in hematological malignancies.{27397}

We also advise you